Early assessment of absorption, distribution, metabolism, and excretion (ADME) is essential in identifying weaker drug candidates early in the discovery process. This reduces the proportion of compounds failing in clinical trials for ADME reasons.
We offer a comprehensive suite of standard in vitro ADME assays and collaborate with our clients to design purposeful screening cascades tailored to each drug discovery program.
We provide:
CYP Induction
Understanding how a drug may impact the body’s metabolic system is a key part of developing safe and effective therapies. At Concept Life Sciences, we offer reliable, cost effective and regulatory-aligned CYP induction studies to help you assess the potential for drug-drug interactions early in development.
Our team focuses on the most clinically relevant CYP450 enzymes— CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19 and CYP3A4 —using well-established in vitro models like cryopreserved human hepatocytes. We measure changes in enzyme activity, mRNA levels, cytotoxicity and protein expression to provide a full picture of induction potential. With the support of sensitive LC-MS/MS based enzyme activity analysis, we ensure data accuracy and consistency you can trust. These insights help de-risk your development program and support confident decision-making as you move your compounds forward. Partner with Concept Life Sciences to navigate the complexities of CYP induction with clarity and precision.
Get a precise quote for your ADME project in less than 24 hours by using our ADME calculator.